Chicken pox in pregnancy Management protocol

 

Maternal Medicine · Clinical Reference

Chickenpox (Varicella)
during Pregnancy

A protocol for prevention, post-exposure prophylaxis, and active infection — for mother and baby.

BASED ON RCOG & ACOG GUIDELINES

1

Initial Assessment & Prevention

Determine Immunity

At the first antenatal visit, take a detailed history of prior chickenpox or shingles infection, or varicella vaccination.

If Non-Immune

• Advise avoidance of contact with anyone with chickenpox or shingles.
• Offer vaccination postnatally — not during pregnancy.
• Delay conception 1 month after vaccination.

2

Management Following Exposure

Step 1

Determine "Significant Exposure"

• Contact type: face-to-face, or same small room for 15+ minutes, with someone who has chickenpox, disseminated shingles, or exposed shingles lesions.
• Infectious window: 24 hours before rash appears → 5 days after.

Step 2

Determine Susceptibility

Urgent VZV IgG blood test for a susceptible woman with significant exposure.

A reliable history of chickenpox, or two vaccine doses, is itself sufficient evidence of immunity in an immunocompetent woman — no further testing needed.

Step 3

Post-Exposure Prophylaxis (PEP)

Offered if VZV IgG negative (non-immune).

First-line

Oral Antiviral Therapy

Aciclovir or valaciclovir — now the recommended first choice. Given Day 7 to Day 14 after exposure.

Second-line

VZIG

Considered if antivirals are contraindicated (e.g. renal impairment) or not tolerated. A blood product giving passive immunity; effective up to 10 days after contact.

3

Management of Active Chickenpox

Immediate Action

Contact the healthcare provider immediately, and isolate from other pregnant women.

Risk Profile

10–20%

Pregnant women who develop pneumonia

0.4–2.0%

Risk of fetal varicella syndrome

1st / early 2nd

Trimester = highest fetal risk window

Maternal risks also include hepatitis and encephalitis. Fetal risk depends on gestational age at infection.

Treatment

Route	When indicated
Oral aciclovir	Presenting within 24 hours of rash onset, ≥20 weeks gestation. Use before 20 weeks should also be considered.
IV aciclovir	All pregnant women with severe chickenpox or signs of complications (e.g. respiratory symptoms).

High-Risk Window: Late Pregnancy

Maternal infection from 5 days before to 2 days after delivery carries a high risk of neonatal death. Requires specialist management in a unit with neonatology expertise.

SOURCES — ROYAL COLLEGE OF OBSTETRICIANS & GYNAECOLOGISTS (RCOG) · AMERICAN COLLEGE OF OBSTETRICIANS & GYNECOLOGISTS (ACOG)
FOR CLINICAL REFERENCE — ALWAYS FOLLOW LOCAL PROTOCOL

EARLY INTERVENTIONS SAVE LIVES

 A 32-year-old G2P1 underwent an intrapartum cesarean for arrest of descent after a prolonged labor. She had several PPH risk factors on admission (prolonged oxytocin exposure, chorioamnionitis concern, and uterine overdistension). Because the unit used quantified blood loss (QBL) and maternal early-warning triggers, she was flagged as “high vigilance” pre-incision: second IV placed, uterotonics prepared, blood bank alerted.

In recovery, the team did not rely on “looks like moderate bleeding.” QBL crossed the major hemorrhage trigger within minutes, while her vitals showed early compensated shock (tachycardia with narrowing pulse pressure). A structured PPH call went out immediately with explicit role allocation: one clinician on uterine tone/uterotonics, one on identifying trauma/retained tissue, anesthesia running resuscitation and labs, and a runner coordinating products.

First-line management was rapid and protocolized: bimanual uterine massage, high-dose oxytocin infusion, additional uterotonics, and tranexamic acid while causes were assessed. Despite transient improvement, bleeding persisted and the uterus remained atonic. A bedside ultrasound showed no clear retained products, and repair of a small vaginal laceration did not change bleeding. Within a short, pre-agreed time window—before profound hypoperfusion—the consultant made the call to return to theatre for definitive surgical hemostasis.

The turning point: early laparotomy before irreversible physiology

On re-laparotomy, the uterus was markedly atonic with diffuse bleeding. The team moved quickly through a step wise escalation:

1. Uterine compression suture (B-Lynch): A B-Lynch suture was placed to provide immediate mechanical compression of the atonic uterus, aiming to preserve fertility and avoid hysterectomy. (B-Lynch is widely used as a uterus-sparing option and has been described with high success in refractory atony when applied promptly.)

2. Bilateral uterine artery ligation: Because oozing continued, bilateral uterine artery ligation was performed as a rapid devascularization step. This approach is commonly incorporated into stepwise surgical management of severe PPH and can reduce ongoing blood loss while other measures take effect.⁽²⁾

3. Bilateral internal iliac (hypogastric) artery ligation: Persistent diffuse bleeding and evolving coagulopathy prompted escalation to bilateral internal iliac artery ligation. This reduced pelvic arterial pulse pressure and bought crucial time for correction of coagulopathy and restoration of circulating volume. The combination of B-Lynch plus internal iliac ligation has been reported as an effective uterus-preserving strategy even in massive PPH complicated by DIC.

In parallel, anesthesia ran a massive hemorrhage resuscitation: active warming, calcium replacement, and goal-directed blood product support (RBC, plasma, platelets, cryoprecipitate/fibrinogen as indicated). Importantly, because the decision for laparotomy happened early, she reached definitive surgical hemostasis before cardiovascular collapse. She stabilized, avoided hysterectomy, and was discharged after an uncomplicated recovery. A debrief emphasized that the uterus was saved not by a single technique, but by timely recognition + decisive escalation.

Why this is a “success story” about early detection

• QBL + early-warning triggers converted “post-op bleeding” into a time-critical diagnosis while she was still in compensated shock.
• A time-bound escalation plan prevented prolonged “medical-only” management as coagulopathy developed.
• Early definitive surgery (B-Lynch → uterine artery ligation → internal iliac ligation) exemplified structured, uterus-sparing escalation that can prevent maternal death from refractory PPH.

The 2026 Acute Pulmonary Embolism (PE) Guidelines

 Massive” and “Submassive” Replaced by Clinical Categories: The first-ever AHA/ACC clinical practice guideline on acute pulmonary embolism drops a new A-to-E severity classification. 

Key Shift:

• The guideline abandons “Massive” and “Sub-massive” labels.

• Instead, it uses clinical severity categories (A–E) to better stratify risk and guide therapy.

• This improves clarity for front-line clinicians and aligns PE care with modern risk-based management.

Simplified Biomedical Waste Color Coding Guide

 

 

🤝 UNFPA SUPPORTED

MCH
Maternal & Child Health

CARBETOCIN IN POSTPARTUM HEMORRHAGE

Preventing and Managing PPH with Long-Acting Oxytocin

Dr. Sujnanendra Mishra

SWARAJ Hospital & Research Institute, Bolangir

Published at drsujnanendra.blogspot.com

💊 What is Carbetocin?

Carbetocin is a synthetic oxytocin analogue—a long-acting uterotonic agent specifically designed to reduce postpartum hemorrhage. Unlike standard oxytocin, carbetocin provides prolonged uterine tone from a single dose, reducing the need for repeat dosing or continuous infusions.

🏥 Clinical Use Cases

1 Cesarean Delivery Prophylaxis

Evidence: Strongest indication across RCT meta-analyses

• ✓ ↓ Additional uterotonics (consistent advantage)
• ✓ ↓ Transfusion requirements
• ✓ ↓ Hemoglobin drop in postoperative period
• ✓ Sustained uterine tone from single dose

2 Vaginal Delivery Prophylaxis

Evidence: Mixed by setting; tailored to high-risk populations

• ✓ Severe PPH reduction in before–after cohorts
• ✓ ↓ Second-line uterotonic need in high-risk births
• ✓ Lower mean blood loss in policy-change analyses
• ✓ Cost-benefit context-dependent

3 Heat-Stable Carbetocin

WHO-Aligned Implementation: Ideal for challenging settings

• No cold-chain requirement
• Reduces oxytocin quality concerns
• Cost savings where comparable to oxytocin
• Improves accessibility in resource-limited areas

💉 Standard Dosage & Administration (Prophylaxis)

100 μg

IV bolus, single dose immediately after delivery of placenta

Operational Advantage: "One-and-done" bolus replaces bolus + infusion workflows, reducing complexity and infusion errors in busy delivery rooms.

📊 Carbetocin vs. Standard Oxytocin

🔽

Additional Uterotonics

Consistent reduction across studies—fewer escalations needed for hemorrhage control

🩸

Transfusion Reduction

Lower transfusion rates in cesarean deliveries; reduced Hb drop postoperatively

⏱️

Sustained Uterine Tone

Single bolus provides prolonged effect—no need for continuous infusion monitoring

✅

Workflow Efficiency

Reduces line burden, infusion errors, and nursing resource allocation in delivery settings

⚠️ Safety & Adverse Effects

• Expected class effects: Nausea, vomiting, flushing, headache, dizziness (similar to oxytocin)
• Hemodynamic monitoring: Monitor BP/HR, especially in neuraxial anesthesia
• Uterine hyperstimulation: Lower postpartum risk than intrapartum use; avoid inadvertent repeat dosing
• Contraindication clarity: Prophylaxis only—local guidelines vary on established PPH treatment

🔴 CRITICAL: Prophylaxis vs. Treatment Distinction

⚡ IMPORTANT: Carbetocin has STRONG EVIDENCE for PPH PROPHYLAXIS (prevention before hemorrhage occurs), but its role in TREATMENT of established/active PPH is NOT well-established and may be OFF-LABEL in many regions.

✓ PROPHYLAXIS (Supported)

• ✓ Given AFTER placenta delivery
• ✓ Prevention of PPH (best evidence)
• ✓ WHO-recommended in many guidelines
• ✓ Reduces additional uterotonic need

✗ TREATMENT (Not Established)

• ✗ For active/established PPH (off-label)
• ✗ Limited RCT evidence for treatment
• ✗ NOT primary recommendation in major guidelines
• ✗ Use second-line agents (misoprostol, ergot, TXA)

⚠️ Disadvantages & Limitations

💰 High Acquisition Cost

Carbetocin is significantly more expensive than standard oxytocin, which may limit adoption in resource-constrained settings despite WHO recommendations. Cost-effectiveness is context-specific and depends on local pricing.

❌ Limited PPH Treatment Evidence

Most high-level evidence supports prophylaxis only. Use for established PPH is off-label in many regions. Standard second-line agents (misoprostol, ergot alkaloids) remain primary treatment options.

📋 Regulatory & Guideline Variation

Approval status and indication vary by country/region. Not all health systems have institutional protocols; off-label use requires local endorsement. WHO guidance supports heat-stable variant but adoption remains patchy globally.

🔄 Single-Dose Limitation

Unlike oxytocin infusion, carbetocin provides prolonged effect from one dose—but if PPH is not prevented by that dose, additional escalation to second-line agents is required. Cannot titrate further carbetocin dosing.

🏥 Supply Chain & Availability

Despite heat-stable advantages, global supply remains limited compared to oxytocin. Procurement timelines and import regulations can delay availability in some countries. Not universally stocked in all delivery facilities.

📊 Mixed Evidence in Vaginal Birth

While cesarean-delivery data are robust, evidence for routine use in vaginal birth is less clear. Before–after cohorts show benefit, but large RCTs comparing carbetocin to oxytocin in vaginal delivery are limited.

⚕️ Similar Adverse Effects

No significant safety advantage over oxytocin. Class-typical side effects (nausea, flushing, hemodynamic changes) still occur. Does not eliminate need for careful hemodynamic monitoring and management.

🚫 Cannot Treat Established PPH

For patients with active hemorrhage, carbetocin is NOT recommended as a primary treatment agent. Ergot alkaloids, misoprostol, tranexamic acid, and supportive measures (compression, suturing, interventional radiology) are standard first-line therapy.

Bottom Line on Limitations: Carbetocin is best viewed as a prophylactic upgrade in resource-appropriate settings—especially where cold-chain infrastructure is poor or where reducing additional uterotonics matters clinically. It is NOT a replacement for active PPH management and should not replace established second-line agents in emergency scenarios.

⭐ Where Carbetocin Shines (Best-Fit Scenarios)

• Cesarean Deliveries: Sustained uterine tone from single dose is particularly desirable
• High-Risk Vaginal Births: Protocol-dependent; reduces second-line uterotonic escalation
• Resource-Constrained Settings: Heat-stable formulation eliminates cold-chain dependency
• Workflow Optimization: Single bolus reduces infusion complexity and staff burden in busy ORs/delivery rooms
• Systems Seeking Efficiency: Cost-offset through reduced transfusions and additional uterotonic requirements

🎯 Key Takeaway

Carbetocin is a powerful, evidence-backed option for PPH prophylaxis—particularly at cesarean and in settings where sustained uterine tone and reduced additional uterotonic requirement matter most. Its heat-stable variant aligns with WHO guidance and supports global maternal health in resource-limited environments.

SWARAJ Hospital & Research Institute

Bolangir, Odisha | Committed to Excellence in Women's Health & Research

UNFPA

MCH

Evidence-Based

Pulmonary Embolism

&nbs

🫁 PULMONARY EMBOLISM (PE)

A Clot That Blocks Blood Flow to the Lungs

⚡ Virchow's Thrombotic Triad

Venous Stasis

• Prolonged bed rest
• Immobilization
• Prolonged sitting
• Heart failure

Endothelial Injury

• Trauma/fractures
• Surgery
• Central lines
• Vasculitis

Hypercoagulability

• Cancer
• Pregnancy
• OCPs/HRT
• Factor V Leiden

🎯 High-Risk Conditions

• Recent surgery (hip/knee)
• Active cancer
• Long-haul travel/flights
• Pregnancy/postpartum
• Central venous lines
• Obesity
• Prior DVT/PE
• COVID-19

⚠️ Signs & Symptoms

• Sudden dyspnea (most common)
• Chest pain (pleuritic)
• Unexplained tachycardia (HR >100)
• Hypoxia
• Syncope/near syncope
• Apprehension/sense of doom
• Leg swelling/pain (DVT)
• Hemoptysis

🔍 Diagnostic Workup

Order of Priority

1

Well's Score → Pre-test probability assessment

2

D-dimer → If low/intermediate probability (⚠️ NOT useful in hospitalized/postop patients)

3

CTPA → GOLD STANDARD (filling defect in pulmonary artery)

📋 Well's Score for PE (Simplified)

Clinical Feature	Points
Clinical signs/symptoms of DVT	+3
PE is #1 diagnosis OR equally likely	+3
Heart rate > 100 bpm	+1.5
Immobilization ≥3 days OR surgery in past 4 weeks	+1.5
Prior DVT/PE	+1.5
Hemoptysis	+1
Malignancy (active/treatment within 6 months)	+1

Interpretation:
≤4 points = PE unlikely → order D-dimer
>4 points = PE likely → proceed to CTPA

🚨 MASSIVE PE RED FLAGS

• Systolic BP < 90 mmHg
• Respiratory arrest or agonal breathing
• Pulseless electrical activity (PEA)
• Altered mental status + hypotension
• Cardiogenic shock
• Classic triad: Syncope + Tachycardia + Hypoxia (found in only 20%)

⏰ Time is lung. Time is life. Call Rapid Response / Code IMMEDIATELY

👨‍⚕️ Immediate Nursing Actions

1️⃣ ASSESS & STABILIZE

• ABCs assessment
• High-flow oxygen (target SpO₂ ≥92%)
• Two large-bore IV access
• Continuous cardiac monitoring
• Bedrest (avoid Valsalva, sudden movement)

2️⃣ PREPARE FOR THERAPY

• Anticoagulation: Heparin (UFH/LMWH)
• ⚠️ Do NOT delay for CTPA
• Thrombolytics (massive PE only): tPA
• Vasopressors if hypotensive

3️⃣ MONITOR COMPLICATIONS

• Bleeding signs (especially on thrombolytics)
• Right heart failure (JVD, edema)
• Recurrent PE symptoms
• Hemodynamic status

4️⃣ CALL FOR HELP

• Rapid Response if unstable
• Code Blue if massive PE
• Consider thrombectomy/embolectomy
• PERT Team consultation

💊 Treatment Quick Reference

PE Severity	Treatment	Anticoagulation Duration
Low-risk (hemodynamically stable)	LMWH / DOAC (Apixaban, Rivaroxaban)	3–6 months
Intermediate-risk (RV strain on echo/troponin+)	LMWH → DOAC or Warfarin	3–12 months
High-risk/Massive (hypotensive)	Thrombolysis (tPA) + Anticoagulation	Minimum 3 months
Contraindication to Anticoag	IVC filter (removable)	Until filter removed

💡 Key Nursing Pearls

• "PE can mimic many things" – Anxiety, pneumonia, COPD, MI, pericarditis
• Syncope + tachycardia + hypoxia → Massive PE until proven otherwise
• Do NOT delay anticoagulation while waiting for CTPA if high clinical suspicion
• D-dimer is NOT useful in hospitalized/postop patients (always elevated)
• Pregnant patients → V/Q scan or CTPA (fetal radiation risk low after 1st trimester)
• Low-risk PE → May be discharged on DOACs (if home safe, no hypoxia, no RV strain)

📚 Patient Education & Discharge

💊 Medication Adherence

Anticoagulants are NOT optional. Missing doses risks recurrent PE. Take medications exactly as prescribed.

🩸 Bleeding Precautions

Report black/tarry stools, blood in urine, large bruises, headache, or vomiting immediately.

🚶 Activity & Movement

Gradual return to activity. Avoid prolonged sitting. Walk hourly. Compression stockings reduce post-thrombotic syndrome.

⚠️ Signs of Recurrence

New dyspnea, chest pain, syncope → Go to ER immediately.

✈️ Travel Safety

Stay mobile, hydrate well, aisle seat. Consider LMWH before long flights (high-risk patients).

🧦 Compression Stockings

20–30 mmHg compression reduces post-thrombotic syndrome risk (swelling, pain).

Clinical Education Resource – Not a Substitute for Full Clinical Judgment

References: ESC Guidelines for Acute PE (2019) | AHA/ACC Venous Thromboembolism Guidelines (2022) | PERT Consortium Protocols

Always follow institutional protocols and consult with healthcare team for patient-specific decisions.

p;